The design of clinical trials is a key aspect to maximizing the possibility to detect a treatment
effect. This fact is particularly challenging in progressive multiple sclerosis (PMS) studies …

Neuromyelitis optica or neuromyelitis optica spectrum disorders (NMOSD) are autoimmune
diseases associated with a disease‐specific autoantibody directed against the water …

Atypical antipsychotic agents, such as clozapine, are used for treating psychosis and
depression and have recently been found to modulate neuroinflammation. We have shown …

Purpose of Review JC polyomavirus (JCPyV) is a significant human pathogen that causes
an asymptomatic infection in the kidney in the majority of the population. In …

In recent years, there has been a significant increase in the therapeutic options available for
the management of relapsing forms of MS. Therapies primarily targeting B cells, including …

Following approval in 1997 of the anti-CD20 antibody rituximab for the treatment of B-NHL
and CLL, many other unconjugated IgG1 MAbs have been tested in pre-clinical and clinical …

The calculation of the sample size needed for a clinical study is the challenge most
frequently put to statisticians, and it is one of the most relevant issues in the study design …

In 2016, new highly active treatment options for relapsing–remitting multiple sclerosis (MS)
emerged. At the same time, large clinical trials in progressive MS highlighted the limitations …

Monoclonal antibodies (mAb) are promising therapeutics in multiple sclerosis and multiple
new candidates have been developed, hence increasing the need for some agreement for …

As we approach the 25th anniversary of the introduction of interferon beta-1b, the first
disease-modifying therapy (DMT) for multiple sclerosis (MS), consensus has emerged that …